Flexion Therapeutics Inc
Flexion Therapeutics Inc (FLXN): 3 pipeline candidates · ~33 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
33.2 months
D/E -3.65 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for Flexion Therapeutics Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.2B
Cash
$136.8M
Quarterly Burn
$14.2M
Runway
33.2 mo
Revenue
$21.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$36.9M
| Holder | Shares | Value |
|---|---|---|
| bank of new york mellon corp | 1,464,345 | $36.9M |
| horizon investments, llc | 504 | $12K |
| osaic holdings, inc. | 225 | $6K |
Frequently asked questions
How many drug candidates are in Flexion Therapeutics Inc's pipeline?
Flexion Therapeutics Inc (FLXN) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Flexion Therapeutics Inc's lead drug candidate?
Flexion Therapeutics Inc's most advanced tracked candidate is fx201 (Phase 1) for osteoarthritis of the knee.
What is Flexion Therapeutics Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Flexion Therapeutics Inc has approximately 33.2 months of cash runway.
What is Flexion Therapeutics Inc's market capitalization?
Flexion Therapeutics Inc's market capitalization is approximately $1.2B.
Who is the CEO of Flexion Therapeutics Inc?
Michael D. Clayman, M.D. is the chief executive officer of Flexion Therapeutics Inc (FLXN).
Get the full picture on Flexion Therapeutics Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.